Scientists from the German Cancer Research Center (DKFZ) recently announced they studied how the human immune response after immunization with the malaria pathogen Plasmodium falciparum (Pf).
Their goal was to find out against which protein components the T helper cells induced in this way are directed. 
Published by the journal Science Immunology on June 10, 2022, this study revealed T helper cells reacted exclusively to the protein sequence of the vaccine strain and showed hardly any cross-reactivity with the naturally occurring pathogen variants. 

The U.S. Centers for Disease Control and Prevention (CDC) reported today the number of pneumonia-related fatalities continues to outpace both COVID-19 and Influenza.
The CDC's National Center for Health Statistics (NCHS) Mortality Surveillance includes data evaluating pneumonia, influenza, and COVID-19 (PIC) fatalities. 
As of June 17, 2022, data collected (82%) for week #19 indicates there were 2,074 pneumonia fatalities in the USA, far surpassing COVID-19 (1,103) and influenza (57).

Leading researchers recently hypothesized that Covid-19 vaccination rates could be associated with influenza vaccination rates.

Lyme disease has continued to spread worldwide, but there’s little scientific agreement on how common is this tick-borne disease.
To resolve this knowledge gap, the open-access journal BMJ Global Health revealed a pooled data analysis on June 13, 2022, that found more than 14% of the world’s population probably has or has had the presence of antibodies to Borrelia burgdorferi sensu lato (Bb)  infection in the blood.
The three regions with the highest reported seroprevalence were Central Europe (21%), Eastern Asia (16%), and Western Europe (13.5%). 

The latest measles outbreak information shows that while very few measles cases were observed during the COVID-19 pandemic, measles cases are now being reported by countries that had previously eliminated or interrupted endemic measles transmission.
The World Health Organization reported worldwide measles cases increased by 79% in the first two months of 2022, compared to the same period in 2021.

The cure rate for nonmetastatic rectal cancer has been improving for decades but often includes unpleasant treatments, wrote Hanna K. Sanoff, M.D., M.P.H. in an Editorial published by The New England Journal of Medicine (NEJM) on June 5, 2022.
Recent phase 3 trial findings have increased treatment intensity to include multiagent chemotherapy in addition to radiation therapy before proctectomy is performed.
Such treatment has resulted in a 3-year disease-free survival rate of up to 77%.

According to findings from a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health, people with HIV have a higher rate of breakthrough COVID-19 infections after vaccination than those without HIV.
In the study published in the peer-review JAMA Network Open on June 7, 2022, the researchers analyzed anonymized health records among nearly 114,000 people fully vaccinated with either two doses of mRNA vaccines or one dose of the viral vector vaccine in late 2021. 

After nine years of refinement at Fred Hutchinson Cancer Center in Seattle, a different kind of HIV vaccine candidate is nearing its first testing in human volunteers.
This innovative HIV vaccine is intended to train a person’s immune system to mount a robust antibody response against the virus that causes AIDS.
The HVTN 301 phase 1 clinical trial is among the first studies to try out this next-generation vaccine concept known as germline targeting. 

According to media reporting yesterday, the number of people in eleven U.S. states who have received a monkeypox virus (MPX) preventive vaccine has reached about 1,200.
CNN reported White House senior director for global health security and biodefense (Dr. Raj Panjabi) stated on June 3, 2022, "We want to ensure that people with high-risk exposures have rapid access to vaccines."
“And 100 treatment courses (sent) to eight jurisdictions, and we have more to offer states."

If the U.S. government declares an influenza pandemic, a new vaccine production facility located in Holly Springs, North Carolina, is certified and ready to go.
New Jersey-based Seqirus announced today that the company's innovative manufacturing facility has successfully achieved all criteria required to establish domestic manufacturing capability for cell-based seasonal and pandemic influenza vaccines as outlined by the Biomedical Advanced Research and Development Authority (BARDA).